Osteoporosis and risk of fracture in patients with diabetes: An update

Aging Clinical and Experimental Research

Volumn 23, Issue 2, 2011, Pages 84-90

  Montagnani, Andrea ^a   Gonnelli, Stefano ^b   Alessandri, Massimo ^a   Nuti, Ranuccio ^b  

^a MISERICORDIA HOSPITAL   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Antidiabetic therapy; Bone turnover; Diabetes mellitus; Osteoporosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; CALCIUM; COLLAGEN; EXENDIN 4; INCRETIN; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SITAGLIPTIN; SOMATOMEDIN C; SULFONYLUREA; VILDAGLIPTIN;

BONE DENSITY; DIABETES MELLITUS; FRACTURE; GLYCEMIC CONTROL; HUMAN; HYPERCALCIURIA; HYPERINSULINEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOPOROSIS; REVIEW; VITAMIN INTAKE;

EID: 79960924005     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: 10.1007/BF03351073     Document Type: Review

References (96)

1. Johnell O, Kanis JA, Oden A et al. Mortality after osteoporotic fractures. Osteoporos Int 2004; 15: 38-42. (Pubitemid 38252438)
2. Tosteson AN, Gabriel SE, Grove MR et al. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 2001; 12: 1042-49.
3. Jiang HX, Majumdar SR, Dick DA et al. Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 2005; 20: 494-500.
4. Kroger H, Tuppurainen M, Honkanen R et al. Bone mineral density and risk factors for osteoporosis - a population-based study of 1600 perimenopausal women. Calcif Tissue Int 1994; 55: 1-7.
5. Johnell O, Gullberg B, Kanis JA et al. Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res 1995; 10: 1802-15.
6. Janghorbani M, Van Dam RM, Willett WC et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 2007; 166: 495-505.
7. Munoz-Torres M, Jodar E, Escobar-Jimenez F et al. Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus. Calcif Tissue Int 1996; 58: 316-9. (Pubitemid 26136794)
8. Miazgowski T, Czekalski S. A 2-year follow-up study on bone mineral density and markers of bone turnover in patients with long-standing insulin-dependent diabetes mellitus. Osteoporos Int 1998; 8: 399-403.
9. Jehle PM, Jehle DR, Mohan S et al. Serum levels of insulin-like growth factor system components and relationship to bone metabolism in type 1 and type 2 diabetes mellitus patients. J Endocrinol 1998; 159: 297-306. (Pubitemid 28520183)
10. Tuominen JT, Impivaara O, Puukka P et al. Bone mineral density in patients with type 1 and type 2 diabetes. Diabetes Care 1999; 22: 1196-200. (Pubitemid 29293977)
11. Gallacher SJ, Fenner JA, Fisher BM et al. An evaluation of bone density and turnover in premenopausal women with type 1 diabetes mellitus. Diabet Med 1993; 10: 129-33.
12. Weber G, Beccaria L, deAngelis M et al. Bone mass in young patients with type I diabetes. Bone Miner 1990; 8: 23-30.
13. Alexopoulou O, Jamart J, Devogelaer JP et al. Bone density and markers of bone remodeling in type 1 male diabetic patients. Diabetes Metab 2006; 32: 453-8. (Pubitemid 44836587)
14. Bjorgaas M, Haug E, Johnsen HJ. The urinary excretion of deoxypyridinium cross-links is higher in diabetic than in nondiabetic adolescents. Calcif Tissue Int 1999; 65: 121-4.
15. Karaguzel G, Akcurin S, Ozdem S et al. Bone mineral density and alterations of bone metabolism in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2006; 19: 805-14. (Pubitemid 44083537)
16. Krakauer JC, McKenna MJ, Buderer NF et al. Bone loss and bone turnover in diabetes. Diabetes 1995; 44: 775-82.
17. Mathiassen B, Nielsen S, Johansen JS et al. Long-term bone loss in insulin-dependent patients with microvascular complications. J Diabetes Complicat 1990; 4: 145-9.
18. Forst T, Pfutzner A, Kann P et al. Peripheral osteopenia in adult patients with insulin-dependent diabetes mellitus. Diabet Med 1995; 12: 874-9.
19. Piepkorn B, Kann P, Forst T et al. Bone mineral density and bone metabolism in diabetes mellitus. Horm Metab Res 1997; 29: 584-91.
20. Mastrandrea LD, Wactawski-Wende J, Donahue RP et al. Young women with type 1 diabetes have lower bone mineral density that persists over time. Diabetes Care 2008; 31: 1729-35.
21. Cummings SR, Nevitt MC, Browner WS et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 767-73.
22. Ivers RQ, Cumming RG, Mitchell P et al. Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care 2001; 24: 1198-203.
23. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001; 24: 1192-7.
24. Wakasugi M, Wakao R, Tawata M et al. Bone mineral density measured by dual energy X-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. Bone 1993; 14: 29-33. (Pubitemid 23081246)
25. Van Daele PLA, Stolk RP, Burger H et al. Bone density in non-insulin-dependent diabetes mellitus. Ann Intern Med 1995; 122: 409-14.
26. Schwartz AV, Sellmeyer DE, Ensrud KE et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001; 86: 32-8. (Pubitemid 32109771)
27. Sosa M, Dominguez M, Navarro MC et al. Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus. J Diabetes Complications 1996; 10: 201-5. (Pubitemid 26270743)
28. Forsen L, Meyer HE, Midthjell K et al. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey. Diabetologia 1999; 42: 920-5. (Pubitemid 29369598)
29. Heath H, Melton LJ, Chu CP. Diabetes mellitus and risk of skeletal fracture. N Engl J Med 1980; 303: 567-70. (Pubitemid 10046835)
30. Melchior TM, Sorensen H, Torp-Pedersen C. Hip and distal ami fracture rates in peri- and postmenopausal insulin-treated diabetic females. J Intern Med 1994; 236: 203-8.
31. Barrett-Connor E, Holbrook TL. Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. JAMA 1992; 268: 3333-7.
32. Isaia GC, Ardissone P, Di Stefano M et al. Bone metabolism in type 2 diabetes mellitus. Acta Diabetol 1999; 36: 35-8.
33. Barrett-Connor E, Holbrook TL. Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. JAMA 1992; 268: 3333-7.
34. Janghorbani M, Feskanich D, Willett WC et al. Prospective study of diabetes mellitus and risk of hip fracture: The Nurses' Health Study. Diab Care 2006; 29: 1573-8. (Pubitemid 44127583)
35. Korpelainen R, Korpelainen J, Heikkinen J et al. Lifestyle factors are associated with osteoporosis in lean women but not in normal and overweight women: a population-based cohort study of 1,222 women. Osteoporos Int 2003; 14: 34-43. (Pubitemid 36267899)
36. Ottenbacher KJ, Ostir GV, Peek MK et al. Diabetes mellitus as a risk factor for hip fracture in Mexican-American older adults. J Gerontol A Biol Sci Med Sci 2002; 57: M648-53.
37. Kelsey JL, Browner WS, Seeley DG et al. Risk factors for fractures of the distal forearm and proximal humerus. The Study of Osteoporotic Fractures Research Group. Am J Epidemiol 1992; 135: 477-89.
38. Meyer HE, Tverdal A, Falch JA. Risk factors for hip fracture in middle-aged Norwegian women and men. Am J Epidemiol 1993; 137: 1203-11. (Pubitemid 23205895)
39. Melton LJ III, Achenbach SJ, O'Fallon WM et al. Secondary osteoporosis and the risk of distal forearm fractures in men and women. Bone 2002; 31: 119-25.
40. Vogt MT, Cauley JA, Tomaino MM et al. Distal radius fractures in older women: a 10-year follow-up study of descriptive characteristics and risk factors. The Study of Osteoporotic Fractures. J Am Geriatr Soc 2002; 50: 97-103.
41. Ahmed LA, Joakimsen RM, Bemtsen GK et al. Diabetes mellitus and the risk of non-vertebral fractures: the Tromsø Study. Osteoporos Int 2006; 17: 495-500.
42. Luetters CM, Keegan TH, Sidney S et al. Risk factors for foot fracture among individuals aged 45 years and older. Osteoporos Int 2004; 15: 957-63. (Pubitemid 40064649)
43. Lipscombe LL, Jamal SA, Booth GL et al. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 2007; 30: 835-41.
44. Adami S. Bone health in diabetes, considerations for clinical management. Current Med Res Opin 2009; 25: 1057-72.
45. Schwartz AV, Hillier TA, Sellmeyer DE et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002; 25: 1749-54. (Pubitemid 41071081)
46. Carnevale V, Romagnoli E, D'Erasmo E. Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 2004; 20: 196-204. (Pubitemid 38714317)
47. Moyer-Mileur LJ, Dixon SB, Quick JL, Askew EW, Murray MA. Bone mineral acquisition in adolescents with type 1 diabetes. J Pediatr 2004; 145: 662.
48. Wientroub S, Eisenberg D, Tardiman R, Weissman SL, Salama R. Is diabetic osteoporosis due to microangiopathy? Lancet 1980; 2: 983.
49. Vogt MT, Cauley JA, Kuller LH, Nevitt MC. Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J Bone Miner Res 1997; 12: 283-9.
50. Campos Pastor MM, Lopez-Ibarra PJ, Escobar-Jimenez F, Serrano Pardo MD, Garcia-Cervigon AG. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int 2000; 11: 455-9.
51. Rigalleau V, Lasseur C, Raffaitin C et al. Bone loss in diabetic patients with chronic kidney disease. Diabet Med 2007; 24: 91-3.
52. Pei Y, Hercz G, Greenwood C et al. Renal osteodystrophy in diabetic patients. Kidney Int 1993; 44: 159-64.
53. Strotmeyer ES, Cauley JA, Schwartz AV et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the Health, Aging, and Body Composition Study. Arch Intern Med 2005; 165: 1612-7.
54. Miao J, Brismar K, Nyren O, Ugarph-Morawski A, Ye W. Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in Sweden. Diabetes Care 2005; 28: 2850-5.
55. Heath H Jr, Lambert PW, Service FJ, Arnaud SB. Calcium homeostasis in diabetes mellitus. J Clin Endocrinol Metab 1979; 49: 462-6. (Pubitemid 10188196)
56. Thrailkill KM, Liu L, Wahl EC et al. Bone formation is impaired in a model of type 1 diabetes. Diabetes 2005; 54: 2875-81. (Pubitemid 41401082)
57. Kemink SA, Hermus AR, Swinkels LM, Lutterman JA, Smals AG. Osteopenia in insulin-dependent diabetes mellitus: prevalence and aspect of pathophysiology. J Endocrinol Invest 2000; 23: 295-303. (Pubitemid 30426548)
58. Takagi M, Kasayama S, Yamamoto T et al. Advanced glycation end products stimulate interleukin-6 production by human bone-derived cells. J Bone Miner Res 1997; 12: 439-46.
59. Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 1996; 11: 931-7. (Pubitemid 26200043)
60. Miyata T, Notoya K, Yoshida K et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 1997; 8: 260-70.
61. Hernandez CJ, Tang SY, Baumbach BM et al. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen crosslinks. Bone 2005; 37: 825-32.
62. Wang X, Shen X, Li X, Agrawal CM. Age-related changes in the collagen network and toughness of bone. Bone 2002; 31: 1-7. (Pubitemid 34754417)
63. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes J Clin Endocrinol Metab 2008; 93: 1013-9.
64. Karsenty G. Minireview: transcriptional control of osteoblast differentiation. Endocrinology 2001; 142: 2731-3.
65. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002; 143: 2376-84. (Pubitemid 34521584)
66. Akune T, Ohba S, Kamekura S et al. PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004; 113: 846-55.
67. Lecka-Czernik B, Gubrij I, Moerman EJ et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J Cell Biochem 1999; 74: 357-71. (Pubitemid 29344887)
68. Bonds DE, Larson JC, Schwartz AV et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006; 91: 3404-10. (Pubitemid 44402111)
69. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005; 48: 1292-9. (Pubitemid 41186093)
70. Räkel A, Sheehy O, Rahmeb E, LeLorier J. Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab 2008; 34: 193-205.
71. Saller A, Maggi S, Romanato G, Tonin P, Crepaldi G. Diabetes and osteoporosis. Aging Clin Exp Res 2008; 20: 280-9.
72. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 2005; 48: 1292-9. (Pubitemid 41186093)
73. Monami M, Cresci B, Colombini A et al. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. Diabetes Care 2008; 31: 199-203.
74. Cortizo AM, Sedlinsky C, McCarthy AD et al. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol 2006; 536: 38-46.
75. Schurman L, McCarthy AD, Sedlinsky C et al. Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 2008; 116: 333-40. (Pubitemid 351947863)
76. Kahn SE, Haffner S, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43. (Pubitemid 44903747)
77. Home PD, Jones NP, Pocock SJ et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007; 24: 626-34. (Pubitemid 46808876)
78. Dormandy JA, Charbonnel B, Eckland D et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
79. Meier C, Kraenzlin ME, Bodmer M et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168: 820-5. (Pubitemid 351620084)
80. Schwartz AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349-54. (Pubitemid 44402103)
81. Grey A, Bolland M, Gamble G et al. The peroxisome-proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007; 92: 1305-10.
82. Rubin GL, Zhao Y, Kalus AM et al. Peroxisome proliferator activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 2000; 60: 1604-8.
83. Seto-Young D, Paliou M, Schlosser J et al. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 2005; 90: 6099-105.
84. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18 (Suppl 2): S10-5. (Pubitemid 34467309)
85. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-9. (Pubitemid 34742565)
86. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32-9.
87. Clowes J, Khosla S, Eastell R. Potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res 2005; 9: 1497-506.
88. Bollag RJ, Zhong Q, Phillips P et al. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 2000, 141: 1228-35.
89. Zhong Q, Itokawa T, Sridhar S et al. Effects of glucose-dependent insulinotropic peptide on osteoclast function. AM J Physiol Endocrinol Metab 2007, 292: E543-8. (Pubitemid 46220579)
90. Xie D, Cheng H, Hamrick M et al. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone 2005, 37: 759-69.
91. Xie D, Zhong Q, Ding KH et al. Glucose-dependent insulinotropic peptide overexpressing transgenic mice have increased bone mass. Bone 2007, 40: 1352-60. (Pubitemid 46566429)
92. Yamada C, Yamada Y, Tsukiyama K et al. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 2008: 149; 574-9.
93. Nuche-Berenguer B, Moreno P, Esbrit P et al. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic and insulin-resistant states. Calcif Tissue Int 2009; 84: 453-61.
94. Nuche-Berenguer B, Moreno P, Portal-Nunez S et al. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regulatory peptides 2010; 159: 61-6.
95. Keegan THM, Schwartz A, Bauer DC, Sellmeyer DE, Kelsey JL. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women. Diabetes Care 2004; 27:1547-53. (Pubitemid 38857424)
96. Johnell O, Kanis JA, Black DM et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res 2004; 19: 764-72. (Pubitemid 41094388)